<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="128425">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430299</url>
  </required_header>
  <id_info>
    <org_study_id>ACC3-US-2010-1</org_study_id>
    <nct_id>NCT01430299</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Accell Evo3 DBM in Instrumented Posterolateral Lumbar Spine Fusion</brief_title>
  <official_title>Efficacy and Safety of Integra Accell Evo3 Demineralized Bone Matrix Instrumented Posterolateral Lumbar Spine Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SeaSpine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SeaSpine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to prospectively evaluate the performance of Integra Accell
      Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a
      retrospective comparison to a historical patient cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Posterolateral fusion by radiographic assessment 12 months post surgery</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Posterolateral fusion by radiographic assessment at 6 and 24 months post surgery</measure>
    <time_frame>6 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interbody fusion by radiographic assessment at 6 months, 12 months and 24 months post surgery</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes</measure>
    <time_frame>Baseline, 6 weeks, 3, 6, 12 and 24 months</time_frame>
    <description>SF-12v2, Oswestry Disability Index, Leg and Back Pain (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication Rates</measure>
    <time_frame>Surgery (baseline), 6 weeks, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Stenosis</condition>
  <condition>Spondylosis</condition>
  <condition>Degenerative Changes</condition>
  <arm_group>
    <arm_group_label>Accell Evo3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Integra Accell Evo3</intervention_name>
    <description>Prospective use Integra Accell Evo3</description>
    <arm_group_label>Accell Evo3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years of age or older at the time of surgery

          -  Require spinal fusion using posterior TLIF, PLF or PLIF in 1 to 3 levels between
             L3-S1

          -  Follow-up radiographic imaging post surgery

        Exclusion Criteria:

          -  Long term users of medications known to inhibit fusion,bone metabolism or epidural
             steroid injections

          -  Immunosuppressive agents, Disease Modifying Anti-rheumatic drugs (DMARDs) or any
             similar immunomodulating drugs, Growth Factors or Insulin

          -  Treated with radiotherapy since their surgery

          -  Medical conditions known to impact bone metabolism, such as Paget's disease,
             osteoporosis

          -  Pregnant or lactating women or women wishing to become pregnant

          -  Prisoner

          -  Participating in an investigational drug or another device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Klineberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of CA - Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of CA-Davis, Dept. of Orthopaedics, Adult &amp; Pediatric Spine Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 12, 2016</lastchanged_date>
  <firstreceived_date>August 30, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spondylosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
